Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer
Clinical trial NCT04373031 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04373031
- Sponsor
- Providence Health & Services
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-12-30
- Primary completion
- 2023-07-08
- Enrollment
- 12
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.